1. Home
  2. ACRS vs RELL Comparison

ACRS vs RELL Comparison

Compare ACRS & RELL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRS
  • RELL
  • Stock Information
  • Founded
  • ACRS 2012
  • RELL 1947
  • Country
  • ACRS United States
  • RELL United States
  • Employees
  • ACRS N/A
  • RELL N/A
  • Industry
  • ACRS Biotechnology: Pharmaceutical Preparations
  • RELL Electronic Components
  • Sector
  • ACRS Health Care
  • RELL Technology
  • Exchange
  • ACRS Nasdaq
  • RELL Nasdaq
  • Market Cap
  • ACRS 165.7M
  • RELL 139.9M
  • IPO Year
  • ACRS 2015
  • RELL N/A
  • Fundamental
  • Price
  • ACRS $1.53
  • RELL $9.66
  • Analyst Decision
  • ACRS Strong Buy
  • RELL
  • Analyst Count
  • ACRS 9
  • RELL 0
  • Target Price
  • ACRS $9.25
  • RELL N/A
  • AVG Volume (30 Days)
  • ACRS 1.4M
  • RELL 32.4K
  • Earning Date
  • ACRS 08-11-2025
  • RELL 07-23-2025
  • Dividend Yield
  • ACRS N/A
  • RELL 2.46%
  • EPS Growth
  • ACRS N/A
  • RELL N/A
  • EPS
  • ACRS N/A
  • RELL N/A
  • Revenue
  • ACRS $17,777,000.00
  • RELL $208,909,000.00
  • Revenue This Year
  • ACRS N/A
  • RELL $5.95
  • Revenue Next Year
  • ACRS $8.11
  • RELL $13.59
  • P/E Ratio
  • ACRS N/A
  • RELL N/A
  • Revenue Growth
  • ACRS N/A
  • RELL 6.34
  • 52 Week Low
  • ACRS $1.05
  • RELL $7.57
  • 52 Week High
  • ACRS $5.17
  • RELL $15.51
  • Technical
  • Relative Strength Index (RSI)
  • ACRS 47.05
  • RELL 46.47
  • Support Level
  • ACRS $1.46
  • RELL $9.60
  • Resistance Level
  • ACRS $1.86
  • RELL $10.75
  • Average True Range (ATR)
  • ACRS 0.12
  • RELL 0.48
  • MACD
  • ACRS -0.02
  • RELL -0.03
  • Stochastic Oscillator
  • ACRS 17.54
  • RELL 13.87

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About RELL Richardson Electronics Ltd.

Richardson Electronics Ltd provides engineered solutions, power grid, and microwave tubes and related consumables, power conversion, RF and microwave components, high-value flat panel detector solutions, replacement parts, tubes, and service training for diagnostic imaging equipment and customized display solutions. Its products have applications in alternative energy, healthcare, aviation, broadcast, communications, industrial, marine, medical, military, scientific, and semiconductor markets. The company segments include PMT (Power and Microwave Technologies Group), Canvys, (Green Energy Solutions) GES, and Healthcare reportable segments. The company derives the majority of its revenues from the PMT segment.

Share on Social Networks: